Logo image of DYAI

DYADIC INTERNATIONAL INC (DYAI) Stock Fundamental Analysis

NASDAQ:DYAI - Nasdaq - US26745T1016 - Common Stock - Currency: USD

0.99  +0.02 (+2.06%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to DYAI. DYAI was compared to 559 industry peers in the Biotechnology industry. Both the profitability and financial health of DYAI have multiple concerns. DYAI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

DYAI had negative earnings in the past year.
DYAI had a negative operating cash flow in the past year.
DYAI had negative earnings in each of the past 5 years.
DYAI had a negative operating cash flow in each of the past 5 years.
DYAI Yearly Net Income VS EBIT VS OCF VS FCFDYAI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

1.2 Ratios

Looking at the Return On Assets, with a value of -73.81%, DYAI is doing worse than 66.67% of the companies in the same industry.
The Return On Equity of DYAI (-630.92%) is worse than 80.29% of its industry peers.
Industry RankSector Rank
ROA -73.81%
ROE -630.92%
ROIC N/A
ROA(3y)-70.74%
ROA(5y)-60.92%
ROE(3y)-146.19%
ROE(5y)-108.49%
ROIC(3y)N/A
ROIC(5y)N/A
DYAI Yearly ROA, ROE, ROICDYAI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200

1.3 Margins

With a decent Gross Margin value of 62.06%, DYAI is doing good in the industry, outperforming 79.57% of the companies in the same industry.
DYAI's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for DYAI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 62.06%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y50.87%
GM growth 5Y38.12%
DYAI Yearly Profit, Operating, Gross MarginsDYAI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5K 10K 15K 20K

More info and screens

2

2. Health

2.1 Basic Checks

Compared to 1 year ago, DYAI has more shares outstanding
Compared to 5 years ago, DYAI has more shares outstanding
The debt/assets ratio for DYAI is higher compared to a year ago.
DYAI Yearly Shares OutstandingDYAI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
DYAI Yearly Total Debt VS Total AssetsDYAI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -14.18, we must say that DYAI is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of DYAI (-14.18) is worse than 79.39% of its industry peers.
A Debt/Equity ratio of 5.40 is on the high side and indicates that DYAI has dependencies on debt financing.
DYAI's Debt to Equity ratio of 5.40 is on the low side compared to the rest of the industry. DYAI is outperformed by 84.05% of its industry peers.
Industry RankSector Rank
Debt/Equity 5.4
Debt/FCF N/A
Altman-Z -14.18
ROIC/WACCN/A
WACCN/A
DYAI Yearly LT Debt VS Equity VS FCFDYAI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

DYAI has a Current Ratio of 3.98. This indicates that DYAI is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.98, DYAI perfoms like the industry average, outperforming 44.98% of the companies in the same industry.
A Quick Ratio of 3.98 indicates that DYAI has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.98, DYAI is in line with its industry, outperforming 47.13% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.98
Quick Ratio 3.98
DYAI Yearly Current Assets VS Current LiabilitesDYAI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 28.57% over the past year.
DYAI shows a strong growth in Revenue. In the last year, the Revenue has grown by 57.20%.
The Revenue has been growing by 15.78% on average over the past years. This is quite good.
EPS 1Y (TTM)28.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)57.2%
Revenue growth 3Y13.35%
Revenue growth 5Y15.78%
Sales Q2Q%14.71%

3.2 Future

Based on estimates for the next years, DYAI will show a very negative growth in Earnings Per Share. The EPS will decrease by -27.75% on average per year.
Based on estimates for the next years, DYAI will show a quite strong growth in Revenue. The Revenue will grow by 13.10% on average per year.
EPS Next Y-63.2%
EPS Next 2Y-27.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year41.86%
Revenue Next 2Y13.1%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
DYAI Yearly Revenue VS EstimatesDYAI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M 8M 10M
DYAI Yearly EPS VS EstimatesDYAI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.1 -0.2 -0.3 -0.4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DYAI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year DYAI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DYAI Price Earnings VS Forward Price EarningsDYAI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DYAI Per share dataDYAI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2 -0.3

4.3 Compensation for Growth

DYAI's earnings are expected to decrease with -27.75% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-27.75%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DYAI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DYADIC INTERNATIONAL INC

NASDAQ:DYAI (6/6/2025, 8:00:01 PM)

0.99

+0.02 (+2.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/amc
Earnings (Next)08-11 2025-08-11
Inst Owners17.3%
Inst Owner Change-1.18%
Ins Owners19.07%
Ins Owner Change0.3%
Market Cap29.79M
Analysts82.86
Price Target9.18 (827.27%)
Short Float %0.72%
Short Ratio4.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-68.42%
EPS NY rev (3m)-68.42%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-18.12%
Revenue NY rev (3m)-18.12%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.38
P/FCF N/A
P/OCF N/A
P/B 32.25
P/tB 32.25
EV/EBITDA N/A
EPS(TTM)-0.2
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0.12
BVpS0.03
TBVpS0.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -73.81%
ROE -630.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 62.06%
FCFM N/A
ROA(3y)-70.74%
ROA(5y)-60.92%
ROE(3y)-146.19%
ROE(5y)-108.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y50.87%
GM growth 5Y38.12%
F-Score3
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 5.4
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.98
Quick Ratio 3.98
Altman-Z -14.18
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-63.2%
EPS Next 2Y-27.75%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)57.2%
Revenue growth 3Y13.35%
Revenue growth 5Y15.78%
Sales Q2Q%14.71%
Revenue Next Year41.86%
Revenue Next 2Y13.1%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y30.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y35.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.16%
OCF growth 3YN/A
OCF growth 5YN/A